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Abstract
Purpose: Recent studies have shown that a new generation of synthetic agonist of Toll-like receptor (TLR) 9 consisting a 39-
39-attached structure and a dCp7-deaza-dG dinucultodie shows more potent immunostimulatory effects in both mouse and
human than conventional CpG oligonucleotides. Radiation therapy (RT) provides a source of tumor antigens that are
released from dying, irradiated, tumor cells without causing systemic immunosuppression. We, therefore, examined effect
of combining RT with a designer synthetic agonist of TLR9 on anti-tumoral immunity, primary tumor growth retardation and
metastases in a murine model of lung cancer.
Methods: Grouped C57BL/6 and congenic B cell deficient mice (B
2/2) bearing footpad 3LL tumors were treated with PBS,
TLR9 agonist, control oligonucelotide, RT or the combination of RT and TLR9 agonist. Immune phenotype of splenocytes
and serum IFN-c and IL-10 levels were analyzed by FACS and ELISA, 24 h after treatment. Tumor growth, lung metastases
and survival rate were monitored and tumor specific antibodies in serum and deposition in tumor tissue were measured by
ELISA and immunofluorescence.
Results: TLR9 agonist expanded and activated B cells and plasmacytoid dendritic cells in wild-type mice and natural killer
DCs (NKDCs) in B cell-deficient (B
2/2) mice bearing ectopic Lewis lung adenocarcinoma (3LL). Combined RT with TLR9
agonist treatment inhibited 3LL tumor growth in both wild type and B
2/2 mice. A strong tumor-specific humoral immune
response (titer: 1/3200) with deposition of mouse IgG auto-antibodies in tumor tissue were found in wildtype mice, whereas
the number of tumor infiltrating NKDCs increased in B
2/2 mice following RT+ TLR9 agonist therapy. Furthermore, mice
receiving combination therapy had fewer lung metastases and a higher survival than single treatment cohorts.
Conclusions: Combination therapy with TLR9 agonist and RT induces systemic anti-tumoral humoral response, augments
tumoral infiltration of NKDCs, reduces pulmonary metastases and improves survival in a murine model of 3LL cancer.
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Introduction
Ionizing radiation therapy (RT) has been used as a standard
treatment modality for many solid tumors [1]. While tumoricidal
properties of RT are instrumental for standard clinical application
of RT, recent preclinical [2–4] and clinical studies [5] have
applied immunomodulatory effects of RT. RT has been shown to
increase the immunogenicity of tumor cells by amplifying the
tumor-specific peptide repertoire [6] and upregulating cell surface
expression of MHC determinants and costimulatory molecules [7].
Furthermore, RT modifies the tumor microenvironment by
enhancing the release of CXCL16 from tumor cells [8] and
upregulating VCAM-1 on the tumor vasculature [9] to favor the
recruitment and trafficking of tumor specific cytotoxic T cells to
tumor tissue. RT also induces the expression of cell surface, death
receptor, Fas, thereby, increasing the susceptibility of irradiated
tumor cells to T cell-mediated killing [10]. These important
findings indicate that RT could be combined with immunotherapy
to improve the control of both localized and systemic tumor
progression [11].
Toll-like receptor (TLR) agonists have been widely used in
cancer therapy due to its ability of inducing potent anti-tumor
immune response [12]. The structure of these agonists contains
highly conserved molecular patterns common to cell surface and
nuclear molecules in pathogens, termed pathogen-associated
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triggers the activation of intracellular signaling pathways through
nuclear factor kB (NF-kB) and mitogen-activated protein kinases
and results not only in the activation of innate effector cells but
also in the induction of adaptive immune response [14]. Among
the fifteen TLR family members, TLR9 receptors recognize
unmethylated cytosine-phosphate-guanosine (CpG) dinucleotides
from bacterial DNA. TLR9 have been studied most extensively
due to its ability of inducing adaptive cellular and humoral
immune response. In mouse and human, TLR9 is only expressed
on plasmacytoid dendritic cells (pDCs), B cells [15] and natural
killer dendritic cells (NKDCs) [16,17]. TLR9 agonists activate
pDCs to secrete type I interferon (IFN) and induce maturation by
upregulating the expression of co-stimulatory molecules such as
CD80 and CD86 [18]. This initiates a range of secondary effects
with eventual activation of natural killer (NK) cells and expansion
of cytotoxic T lymphocytes (CTLs). TLR9 agonists also enhance
the differentiation of B cells into antibody-secreting plasma cells
and could potentially eradicate tumor cells through antibody
dependent cellular cytotoxicity (ADCC) [19–21]. Furthermore,
recent study has shown that TLR9 agonist dramatically increases
the number of NKDCs in vivo and induces NKDCs to secrete
IFN-c via the autocrine effects of IL-12 [16]. The unique ability of
NKDCs to directly lyse tumor cells provides another anti-tumor
pathway mediated by TLR9 agonist.
Most of the oligodeoxynucleotide (ODN) agonists for TLR9
contain unmethylated CpG dinucleotides motifs, which are
relatively common in bacterial DNA. CpG DNA has shown
efficacy in the treatment of various cancers in mouse models but
exhibited poor efficacy in primate system, including human
clinical trial [22]. This has led to the discovery of new ODN by
synthesizing a cytosine-phosphate-29-deoxy- 7-deazaguanosine
dinucleotide (CpR) motifs which showed more potent stimulating
effect in mouse, monkeys and human [23]. This new generation of
TLR9 agonist induces different cytokine profiles (higher or similar
levels of IL-12 and lower IL-6) as compared with CpG ODN [24].
Recent studies have shown that these novel agonists of TLR9
induced mucosal Th1 immune responses in mouse [25], increased
the sensitivity of human non small cell lung cancer (NSCLC) cell
lines to chemotherapy [26] and inhibited the growth of murine
CT26 colon tumor, B16.F0 melanoma and human breast cancers
in vivo [27].
Although many preclinical studies utilizing TLR9 agonists have
induced strong anti-tumoral immune response, TLR9 agonist is
unable to control macroscopic primary tumors. Thus TLR9
agonists are considered as an adjuvant treatment for cancer
patients that can be combined with traditional local therapies,
such as, RT. Radiation therapy has great advantages over other
traditional therapies such as chemotherapy because of the absence
of systemic immunosuppression while presenting a source of tumor
antigens, released from irradiated, dying tumor cells. This focal
effect of RT enables the potential of a strong synergistic
therapeutic effect if combined with immunostimulatory agents,
such as TLR9 agonists. TLR9 agonists, CpG ODNs, have been
combined with RT in various preclinical tumor models, such as,
lung, melanoma and fibrosarcoma [28–31]. However, most
experiments were performed with standard CpG oligonucleotides
that have been shown to be highly active in murine models, while
showing limited activity in humans. Previous reports also failed to
characterize the cellular elements that mediate the anti-tumoral
immunity after combination therapies with TLR9 and RT. We,
therefore, examined the effect of combining RT with a designer
TLR9 agonist that have been specifically developed to bind and
activate primate and mouse TLR9 receptors. In this study, we
have shown that combined RT and TLR9 agonist administration
has synergistic anti-tumor effect in mice bearing a murine lung
adenocarcinoma with improved primary tumor growth retarda-
tion and reduction of systemic pulmonary metastases. We
demonstrate that two pathways could mediate this effect. First,
RT enhances the generation of tumor-specific antibodies, possibly
by amplifying the release of ‘‘tumor-specific’’ antigen pool for
antigen presenting cells (APCs), such as, plasmacytoid dendritic
cells (pDCs) and B-lymphocytes, while TLR9 agonists provide the
activating signal for adaptive anti-tumoral immunity. Second, RT
increases the penetration of antibodies and innate effector cells
(NKDCs) into the tumor tissue by modifying tumor microenvi-
ronment.
Materials and Methods
Mice and Tumor Cell Line
Male C57BL/6J (National Cancer Institute, Bethesda, MD) and
congenic B cell deficient mice (Igh-6
tm1Cgn, The Jackson
Laboratory, Bar Harbor, ME), 4–6 weeks of age, were bred and
maintained at the Animal Resource Facility at Albert Einstein
College of Medicine. All the animal protocols were approved by
Institutional Animal Care committee and were performed
following facility guidelines. Lewis lung carcinoma (3LL) cells
(American Type Culture Collection, Manassas, VA) was propa-
gated in high glucose DMEM supplemented with 10% FBS,
sodium pyruvate, non-essential amino acids and 100 U/ml of
penicillin and streptomycin (Invitrogen, Carlsbad, CA). Cells were
maintained in a 37uC humidified incubator under 5% CO2.
TLR9 Agonist
A CpR containing TLR9 agonist and a control oligonucleotide
with CpC substitution, were synthesized at Idera Pharmaceuticals
as described previously [24,32]. The final product was 95% pure
and endotoxin was less than 0.1 EU/mL by the Limulus assay
(Bio-Whittaker Lonza Walkersville Inc., Walkersville, MD).
TLR9 agonist and the control oligonucleotide were dissolved in
PBS at the concentration of 2 mg/ml and stored at 220uC until
use.
Experimental Design
The immunomodulatory effect of TLR agonist and RT was
tested in both short term and long term animal studies. Mice were
inoculated with 1610
5 3LL cells on day 0 and were divided into 5
groups that received either no treatment, 20 Gy radiation of the
tumor tissue, only control oligo, only TLR9 agonist, or the
combination of irradiation of the tumor, followed by TLR9
agonist injection on day 14. For analysis of short term effect on
splenoctyes, both wildtype and B cell deficient mice (n=25 each)
were sacrificed on day 15 and the phenotype of splenoctyes was
analyzed by flow cytometry (Figure 1A). For analysis of long term
effect on tumor growth and immune response, 40 wild type and 50
B cell deficient mice received different treatments were sacrificed
on day 35 and splenocytes, tumor tissue and sera were collected for
the use of immunological studies (ELISA, ELISpot and Immuno-
fluorescence. Figure 1B). Thirty five wildtype mice were kept alive
and were used for survival studies after tumor amputation on day
49. Detailed treatment procedure is explained in each method
section.
Phenotypic Analysis of Splenocytes by Flow Cytometry
Monoclonal antibodies specific for CD3, CD4, CD8, CD69,
B220, NK1.1 and CD11c were obtained from BD bioscience (San
Jose, CA). Phenotypic analysis of splenocytes in mice was
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were anesthetized and then spleen was removed and minced in
2 ml of PBS and ground with a plunger. The cell suspension was
passed through a 70 micron cell strainer (BD bioscience, San Jose,
CA, USA) and erythrocytes were removed by hemolysis using
a lysis buffer (BD bioscience, San Jose, CA, USA). Cells were then
Figure 1. Experimental schema. The immunomodulatory effect of TLR agonist and RT was tested in both short term (A) and long term animal
studies (B). Experiments were carried out on both C57BL/6 wildtype and cogenic B cell deficient mice. Mice were inoculated with 1610
5 3LL cells on
day 0 and were divided into 5 groups (n=15/group for wildtype and n=10/group for B cell deficient mice) that received either no treatment, 20 Gy
RT of the primary tumor on day 14 post-tumor inoculation, only control oligo, only TLR9 agonist, or the combination of tumor RT, followed
immediately by TLR9 agonist injection on day 14. For short term studies, 25 wildtype or B cell deficient mice were sacrificed on day 15 and
splenocytes were harvested for flow cytometry. For long term studies, 75 wildtype and 50 B cell deficient mice were used. TLR9 agonist was injected
subcutaneously, twice a week for three weeks (from day 14 to 35). The tumor volume was measured at 1–3-day intervals with a vernier caliper. Of the
75 wildtype mice, 40 mice were sacrificed on day 35 for immunological studies and the remaining 35 mice were used for survival studies. For B cell
deficient mice, all of them were sacrificed on day 35 and were used for immunological studies.
doi:10.1371/journal.pone.0038111.g001
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FACScan flow cytometer with Cellquest software. The relative
proportions of lymphocyte subpopulations were determined as
percentages of the total numbers of cells in a lymphogate defined
by forward and side scatter properties.
Detection of Serum Cytokine Levels by ELISA
Serum cytokine levels in mice treated with TLR9 agonist were
detected by a commercial Th1/Th2 ELISA kit (eBioscience, San
Diego, CA, USA). Briefly, serum samples were diluted 4 times with
assay buffer and added into plates that were precoated with
capture antibody. After 2 hours’ incubation, plates were washed 5
times with PBS-T and incubated with detection antibody followed
by strepavidin-HRP. Plates were developed with TMB substrate
for 30 minutes at room temperature, and the reaction was stopped
by adding 1M H2SO4. Plates were read at 450 nm and
concentrations were calculated according to the manufacturer’s
instructions.
Analysis of Antibodies and Lymphocytes Infiltration by
Immunofluorescence
Two days after RT and/or TLR9 agonist injection, mice were
sacrificed and tumors were surgically excised and embedded in
tissue freezing medium (Electron Microscopy Sciences, Hatfield,
PA, USA). Frozen tumor tissues were then sectioned at 5 mm
thickness and stored in 220uC until use. For staining the NKDC
infiltration in the tumor tissue, cryostat sections were aired dried,
fixed in acetone and stained with anti-mouse CD11c monoclonal
antibody (eBioscience, San Diego, CA, USA). After washing,
sections were incubated with FITC-conjugated anti-hamster IgG
(eBioscience, San Diego, CA, USA) and PE-CY7-conjugated anti-
mouse NK1.1. For detecting the antibody infiltration, sections
were stained with FITC-conjugated rabbit anti-mouse IgG. After
30 minutes incubation, sections were washed and covered by
hardset mounting medium with DAPI (Vector Laboratories,
Burlingame, CA, USA). Sections were subsequently visualized
under a Leica SP2 AOBS Confocal microscope (Leica Micro-
systems, Bannockburn, IL, USA).
Detection of Serum Tumor Specific Antibodies by
Indirect ELISA
Titers of tumor specific antibodies in serum were measured by
indirect ELISA assay as described previously [33]. Microtitre
plates (eBioscience, San Diego, CA, USA) were coated with
10 mg/ml protein from 3LL cell lysate in coating buffer at 4uC
overnight. The wells were blocked with 3% BSA in PBS (pH 7.2)
at room temperature for 1 hour. Serum was incubated at two-fold
serial dilution (from 1:100 to 1:12800) at room temperature for 3
hours. Plates were washed in PBS-Tween (0.05%) twice for 10 min
each and incubated with goat anti-mouse IgG-HRP conjugate
(1:2000, BD bioscience, San Jose, CA, USA) at room temperature
for 1 h. Plates were washed with PBS-T and developed with TMD
substrate (eBioscience, San Diego, CA, USA) for 30 minutes at
room temperature in the dark. The reaction was stopped with an
acid stop solution and plates were read at 450 nm on ELISA
reader.
The total IgG titer in mouse serum was measured by an Easy-
Titer Mouse IgG Assay Kit (Thermo Fisher Scientific, Rockford,
IL). Briefly, serum samples were incubated with anti IgG-
sensitized beads for 5 minutes at room temperature and the
reaction was stopped by adding equal volume of blocking buffer to
the mixture. The absorbance was measured at 405 nm or 340 nm
and sample total IgG titer was calculated according to the
manufacturer’s instructions.
Detection of Spleen Tumor Specific T Cells by ELISPOT
Assay
The IFN-c release ELISPOT assay was performed as described
previously with slight modifications, using a commercial kit
(MABTECH, Stockholm, Sweden). Plates (Millipore, Bedford,
MA, USA) were coated overnight with anti-mouse IFN-c mono-
clonal antibody (clone: AN18, 15 mg/ml) and washed six times.
After blocking with 10% FBS, fresh isolated spleenocytes (2.5610
5
cells per well) were added together with RPMI 1640 medium,
PMA (5 ng/ml) and Ionomycin (500 ng/ml), irradiated 3LL cells
(20 Gy, 2610
4 cells per well), MUT1 peptide (FEQNTAQP,
10 mg/ml) respectively. After incubation for 40 hours at 37uC,
cells were removed, and the plates were developed with a second
(biotinylated) antibody (clone: R4-6A2, 1 mg/ml) to mouse IFN-c
and streptavidin-alkaline phosphatase. Plates were developed with
BCIP/NBT substrate (Sigma-Aldrich, St. Louis, MO, USA) for 20
minutes at room temperature in the dark, and the reaction was
stopped by rinsing plates with tap water. The membranes were air
dried, and spots were counted using an automatic ELISOT reader
(Autoimmun Diagnostika, Strassberg, Germany).
Generation of Tumor Growth Curve, Enumeration of
Lung Metastases and Survival Analysis
A total of 75 wildtype and 50 B cell deficient mice were
injected subcutaneously with 1610
5 3LL cells on the dorsum of
right foot. Fourteen days after tumor transplant, mice were
divided into 5 groups (n=15/group for wildtype and n=10/
group for B cell deficient mice) that received either no treatment,
20 Gy radiation of the tumor tissue, only control oligo, only
TLR9 agonist, or the combination of irradiation of the tumor,
followed by TLR9 agonist injection. The irradiation was
performed using a 40 MGC Philips orthovoltage unit operating
at 320 kVp, 5 mA, and 0.5 mm copper filtration (2.60 Gy/min
exposures to the dorsum of the footpad at 31-cm source of
surface distance). Immediately after irradiation, mice from
related groups were injected subcutaneously with TLR9 agonist
on the interscapular region with doses of 10 mg/kg body weight
for monitoring of cytokines and immune response. For tumor
studies, TLR9 agonist (1 mg/kg body weight) was injected
subcutaneously, twice a week for three weeks. The tumor growth
curve was generated by measuring three orthogonal tumor
diameters (L6W6H) at 1–3-day intervals with a vernier caliper.
Of the 75 wildtype mice, 40 mice were sacrificed 35 days after
tumor inoculation and the remaining 35 mice were used for
survival studies. Since 20 Gy of RT was not curative for these
tumors, we performed below-knee amputation of the limb with
tumors, 49 days after tumor innoculation for survival studies (see
Figure 1B for detailed schema).
Statistical Analysis
Statistical analyses were performed using Prism 4.0 software
(GraphPad Software, San Diego, CA, USA). The difference of
serum cytokine levels, lymphocyte frequencies and tumor growth
rate among control and treated mice was analyzed by one-way
ANOVA. Survival rate of mice after treatment was analyzed using
Log-rank (Mantel-Cox) Test. A p value of ,0.05 is considered
significant.
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Immunomodulation by TLR9 Agonist in Tumor-bearing
C57BL/6 Mice
TLR9 is expressed in B cells, pDCs and NKDCs. We examined
whether the TLR9 ligand, TLR9 agonist could activate TLR9-
expressing cells in vivo and analyzed the number and phenotype of
splenic CD4+ T helper cells, CD8+ T cells, B cells, pDCs and
NKDCs in tumor-bearing mice, 24 hours after TLR9 agonist
administration (10 mg/kg body weight, s.c). Both active (TLR9
agonist) and nonactive (control oligo) compounds were tested in
this study. As shown in Table 1, TLR9 agonist causes dramatic
splenomegaly in mice (p,0.001) as compared with untreated and
control oligo-treated mice, indicating an expansion of splenocytes
with TLR9 agonist. Compared to untreated and control oligo-
treated, tumor-bearing mice, TLR9 agonist selectively induced the
proliferation of TLR9-expressing splenocytes, including B220+ B
cells (p,0.001), Cd11c+B220+NK1.1-CD80+ activated pDCs
(p,0.001) and CD11c+B220-NK1.1+ NKDCs (p,0.05) but
reduced the percentage of CD3+CD4+ and CD3+CD8+ T cells
(p,,0.001) (Table 1). These results are similar to the effect of
TLR9 agonist in naı ¨ve mice without any tumors (data not shown)
and confirm that TLR9 agonists activate TLR9+ cells with
amplification of B cells, pDCs and NKDCs.
Immunomodulation by RT+TLR9 Agonist in Tumor-
bearing C57BL/6 Mice
Radiation is known to induce apoptosis in lymphocytes and
other immune effector cells. Thus it is possible that RT could be
deleterious for immune activation by TLR9 agonist. We therefore
examined the effect of RT on various phenotypes of splenocytes.
Previous report by Mason et al demonstrated that combination
treatment with CpG oligonucleotides and a single fraction RT of
20 Gy was superior in tumor control, compared to a combination
therapy of CpG and fractionated RT of 20 Gy [30]. In another
report, single-dose RT was shown to be superior to fractionated
RT in inducing tumor-specific T cells [9]. We, therefore,
examined the immunomodulatory properties of a single fraction
of 20 Gy delivered to a mouse Lewis lung adenocarcinoma, 3LL,
grown on the dorsal aspect of the foot in C57BL/6 mice in
combination with subcutaneous injection of TLR9 agonist.
As shown in Table 1, animals treated with RT alone had larger
spleen weight, compared to untreated controls (0.3060.04 g in
RT versus 0.1260.01 g in untreated controls; P,0.001). However
RT did not alter the percentage of T cells, B cells, pDCs and
NKDCs, nor did RT induce their activation. Treatment with
TLR9 agonist altered the relative percentage of splenocytes with
potent proliferation of B cells, pDCs and NKDCs in animals that
received combination RT and TLR9 agonist. There was no
apparent difference of the immune phenotype of splenocytes
between RT+TLR9 agonist and TLR9 agonist cohorts. Although
the percentage of T cells was decreased after RT+TLR9 agonist
treatment, TLR9 agonist activated CD8+T cells by upregualting
the expression of CD69 on the cell surface. As shown in Figure 2A,
more than half of the CD8+ T cells in the splenocyte population
were dramatically activated and expressed the activation marker
CD69+ after TLR9 agonist (61.765.7%) or RT+TLR9 agonist
(51.467.8% CD69+) treatment. In contrast, only less than 5% of
CD8+ T cells were activated in untreated and RT alone
splenocytes. Besides activating CD8 T cells, TLR9 agonist
treatment also activated B cells, pDCs and NKDCs, as evidenced
by expression of activation markers, CD69 in lymphocytes and
CD80 in DCs.
We next analyzed the release of Th1 and Th2 cytokines in the
blood, 4 hours after RT and/or TLR9 agonist injection. As shown
in Figure 2B, TLR9 agonist increased the serum levels of both
IFN-c (367619 pg/ml) and IL-10 (5986130 pg/ml) as compared
with untreated, control oligo and RT alone (all levels ,10 pg/ml).
Addition of RT induced a similar level of IL-10 release
(662644 pg/ml) but downregulated the secretion of IFN-c
(14.664.8 pg/ml). The decreased IFN-c/IL-10 ratio indicates
addition of RT to TLR9 agonist treatment induces polarization
towards a Th2-mediated humoral immune response. This
correlated with the proliferation and activation of B cells and
reduced number of T cells in mouse spleen after RT+TLR9
agonist treatment.
Local RT Augments the TLR9 Agonist-induced Tumor-
reactive Humoral but not Cellular Immune response
We next determined whether combination treatment of
RT+TLR9 agonist induces a systemic tumor-specific immune
response in vivo. Mice with palpable 3LL tumors received 20 Gy
single fraction RT and TLR9 agonist and control oligo twice
a week for 3 weeks with subcutaneous injection. One week after
last injection, mice were sacrificed and splenocytes and serum were
collected for the detection of cellular and humoral immune
response. As shown in Figure 3A, RT+TLR9 agonist treatment
induced a potent IgG antibody response against 3LL tumor, as
analyzed by indirect ELISA with 3LL tumor lysate coated as
antigen on the ELISA plates. A weaker antibody titer was also
observed in mice treated with RT alone while no significant
antibody production was detected in untreated, TLR9 agonist and
control oligo cohort. At a serum dilution of 1:1600, RT+TLR9
agonist induced a significant level of tumor-reactive antibody, as
compared with untreated (n=8, p,0.05) and TLR9 agonist alone
cohorts (n=8, p,0.05). The total IgG titer was not significantly
Table 1. TLR9 agonist induces the proliferation of TLR9-expression splenocytes in mice bearing an ectopic 3LL footpad tumor.
Treatment Spleen Weight (g) Percentage in total splenoctyes (%)
B cells pDCs NKDCs CD3+CD4+ CD3+CD8+
NT 0.1260.01 53.663.2 1.160.1 2.260.4 22.263.8 14.962.1
Control oligo 0.1060.04 55.563.6 1.660.5 2.761.1 22.262.8 15.762.8
TLR9 agonist 0.4660.04(***)
1 71.768.8(***) 2.760.9(***) 3.760.8(*) 10.062.9(***) 6.961.5(***)
RT 0.3060.04(***) 54.664.2 1.060.2 2.560.7 19.863.9 14.361.9
RT+TLR9 agonist 0.4660.04(***) 72.963.0(**) 3.060.5(**) 5.060.7(**) 10.162.5(**) 6.561.7(***)
1Significant different when compared with NT (No Treatment) group; p values are expressed as ‘‘***’’ (p,0.001); ‘‘**’’ (p,0.01) and ‘‘*’’ (p,0.05).
doi:10.1371/journal.pone.0038111.t001
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in RT and combined RT+TLR9 agonist cohort (Figure 3B).
Since anti-tumoral IgG titers were induced after RT+TLR9
agonist treatment, we next examined whether these auto-
antibodies were bound to the irradiated tumor tissue in situ.
Fresh frozen sections of tumors were prepared from animals, 1
week after the last injection of TLR9 agonist and stained with
hamster anti-mouse IgG. As negative control, we stained the fresh
frozen tumor sections with FITC-labeled hamster IgG antibody.
As seen in Figure 3C, RT increased the deposition of mouse IgG
auto-antibodies on the tumor tissue, as noted by increased
immunofluroscence in RT and RT+TLR9 agonist tumor cohorts.
Tumor specimens from untreated and TLR9 agonist-treated
animals exhibited very weak immunofluroscence, indicating no
deposition of auto-antibodies in tumor tissue in situ. There was no
binding of hamster IgG isotype control to the tumor specimen
indicating that the direct immunofluroscence assay was specific.
These results suggest that RT either induces tumor neoantigens or
increase the distribution and binding of auto-antibodies to the
tumor tissue.
We further analyzed the tumor-specific cellular immune
response in these animals. Splenocytes were cocultured with
Figure 2. TLR9 agonist activates pDCs, NKDCs and B cells and increases the release of Th1 and Th2 cytokines in tumor-bearing
C57BL/6 mice. C57BL/6 mice bearing 3LL tumor were divided into 5 groups receiving either PBS, control oligo, TLR9 agonist, RT (20 Gy) or RT+TLR9
agonist. Splenocytes and sera were harvested 24 hours after treatment. The activation of CD8+ T cells, B cells, pDCs and NKDCs was analyzed by flow
cytometry (A) and the release of IFN-c and IL-10 was analyzed by ELISA (B).
doi:10.1371/journal.pone.0038111.g002
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antigenic peptide MUT1 or PMA+Ionomycin for 40 hours and
the release of IFN-c was detected by ELISpot assay. No tumor
specific IFN-c release was observed in any cohort, suggesting the
absence of a measurable cellular T cell response (see Figure S1).
These results correlate with decreased IFN-c/IL-10 ratio observed
in mice treated with RT+TLR9 agonist and confirm the potential
immunomodulatory role of single fraction RT in polarizing a Th2-
mediated humoral immune response.
RT+TLR9 Agonist Treatment Inhibits Tumor Progression
in both C57BL/6 and Congenic B Cell Deficient Igh-
6
tm1Cgn Mice
To evaluate the therapeutic effect of RT+TLR9 agonist
treatment on the tumor, a tumor growth curve was generated
by measuring the tumor volume at 1–3-day intervals. As shown in
Figure 4, significant tumor growth retardation was seen in mice
treated with RT+TLR9 agonist as compared with untreated mice
(p,0.01). Animals treated with RT or TLR9 agonist alone also
exhibited initial tumor growth retardation in the first two weeks
post-treatment but the tumors eventually regrew after treatments
were stopped. To further validate whether this anti-tumor effect
was mediated by the tumor-specific humoral response generated
by RT+TLR9 agonist, the tumor growth study was performed in
congenic B cell deficient mice, which lacks the ability to produce
antibody. Surprisingly, RT+TLR9 agonist still induced significant
tumor growth retardation as compared with untreated mice
(p,0.01). However, there was no difference between RT alone
and RT+TLR9 agonist cohort during the first 11 days indicating
a dominant RT effect over TLR9 agonist. The tumor treated with
RT alone regrew after 14 days while tumor treated with
RT+TLR9 agonist remained stabilized. This result suggests that
mediators other than antibodies might be also involved in the
generation of anti-tumor effect by RT+TLR9 agonist.
RT Enhances the Infiltration of TLR9 Agonist-activated
NKDCs in Tumor Tissues
In B cell deficient mice, B cells and pDCs are only less than
1.5% of the whole splenocytes population, while T cells and NK
cells consist of over 60% of the splenocytes (See Table S1). To
investigate the mechanism of TLR9 agonist+RT induced anti-
tumor effect in these mice, we first examined whether tumor-
specific T cell immune response is induced by IFN-c ELISPOT
assay. As noted in the wild-type mice, these mice did not develop
a detectable T cell-mediated immune response to 3LL cells in any
of the treatment cohorts (see Figure S1). We, therefore, examined
the immunoprotective role of CD11c+B220-NK1.1+ NKDCs,
which also express TLR9 in B cell-deficient mice. While NKDCs
consist of 25.4611.1% of the splenic DC population in these mice,
TLR9 agonist treatment significantly increased the proportion of
CD11c+B220-NK1.1+ NKDCs (Figure 5. TLR9 agonist,
64.463.4% vs. untreated, 24.3369.7%, p,0.001) while reducing
the percentage of conventional CD11c+B220-NK1.1- DCs
(30.969.4%) (See Table S2). Although RT alone resulted in
a slight increase in NKDCs (RT, 33.668.1% vs. untreated;
p.0.05, ns), addition of TLR9 agonist to RT increased the
percentage of NKDCs to significantly higher levels (RT+TLR9
agonist, 58.665.8% versus untreated; p,0.001). The activation
phenotype of NKDCs from mice treated with RT or control oligo
were not different from those from the untreated mice. However,
45–67% of the NKDCs from TLR9 agonist-treated mice
upregulated the expression of the activation markers for DCs,
CD80 and CD86 (Figure 5), indicating that TLR9 agonist
treatment resulted in proliferation and activation of NKDCs.
Next we analyzed whether RT could facilitate the infiltration of
TLR9 agonist-activated NKDCs in the irradiated tumor tissues.
As shown in Figure 6, RT+TLR9 agonist treatment induced
a significant infiltration of NKDC in the tumor tissue while TLR9
agonist and RT alone induced a slight infiltration of only
Figure 3. RT enhances TLR9 agonist induced tumor specific humoral immune response. Sera from tumor bearing mice treated with either
PBS, control oligo, TLR9 agonist, RT (20 Gy) or combined RT and TLR9 agonist were analyzed for the presence of tumor specific antibodies by indirect
ELISA coated with total 3LL tumor lysate (A). The total IgG titer was evaluated by an Easy-Titer Mouse IgG Assay Kit (B) and the infiltration of IgG
antibody was visualized by confocal microscope after stained with FITC conjugated anti-mouse IgG (C).
doi:10.1371/journal.pone.0038111.g003
Figure 4. RT+TLR9 agonist treatment inhibits tumor progression in both C57BL/6 and congenic B cell deficient mice. Wild type
(C57BL/6) or congenic B cell deficient mice (Igh-6
tm1Cgn) bearing 3LL tumors were divided into 5 groups receiving either PBS, control oligo, TLR9
agonist, RT (20 Gy) or RT+TLR9 agonist. Tumor growth curves were generated by measuring three orthogonal tumor diameters at 1–3-day intervals
with a vernier caliper.
doi:10.1371/journal.pone.0038111.g004
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infiltration of NKDCs after TLR9 agonist treatment suggests that
these immune effector cells might have direct contribution to the
tumoricidal effects of combination treatment in B cell-deficient
mice.
RT+TLR9 Agonist Treatment Prevents Tumor Recurrence
and Metastasis and Improves Survival
Since mouse with Lewis lung adenocarcinoma develop sponta-
neous pulmonary metastases, we investigated whether combina-
tion treatment could prevent tumor recurrence and metastases. In
order to study the effect of systemic metastases on survival, the
primary tumors were removed from all animal cohorts (n=7/
group), 49 days after tumor inoculation (see Figure 1B). As shown
in Figure 7A, animals from untreated, control oligo and RT
cohorts developed gross pulmonary metastases and died within 50
days after tumor removal. In contrast, RT+TLR9 agonist
treatment significantly reduced the number of lung metastases
and improved survival (median survival time RT+TLR9 agonist,
78 days vs. untreated 38 days; p,0.005 log-rank test; Figure 7B)
with 40% of the animals surviving more than 150 days. These
results indicate that combined TLR9 agonist and RT treatment
could provide both local and systemic protection against 3LL
tumor.
Discussion
TLR9 agonists have been widely used in cancer therapy due to
its ability of inducing potent anti-tumor immune response [12]. In
the present study, we have evaluated the potential of combining
single fraction RT with a new generation of synthetic agonist of
TLR9, consisting of a 39-39-attached structure and a CpR motif
that shows potent immunostimulatory effects in diverse vertebrate
species, including human, monkey, pig, horse, sheep, goat, rat, and
chicken [34]. This type of oligonucleotides has great advantage
over conventional CpG oligonucleotides because of the poor
responsiveness of CpG ODN in human clinical trials. By
combining TLR9 agonist with RT, we demonstrate a potent
synergistic local and systemic tumoricidal effect in mice with 3LL
tumors. Consistent with previous studies, TLR9 agonist induced
spleen enlargement in mice and induced the proliferation of
TLR9-expressing splenocytes, including, B220+ B cells,
Cd11c+B220+NK1.1-CD80+ pDCs and CD11c+B220-NK1.1+
NKDCs. Furthermore, it induced the activation of B and T cells
and pDCs with release of IFN-c and IL-12 in the serum.
Interestingly, addition of primary tumor RT caused minimal
changes in the phenotype of splenocytes suggesting that RT does
not suppress the immunomodulatory effects of TLR9 agonist.
However, the serum cytokine profile was different between RT
and RT+TLR9 agonist cohorts. RT reduced the levels of serum
IFN-c while maintaining the serum IL-10 levels, compared to
animals treated with RT+TLR9 agonist. These results suggest that
Figure 5. RT induced the proliferation and activation of NKDCs in congenic B cell deficient mice. Splenocytes from B cell deficient mice
treated with either PBS, control oligo, TLR9 agonist, RT (20 Gy) or RT+TLR9 agonist were stained with anti-CD11c, NK1.1, B220, CD80 and CD86
antibodies and the percentage of activated NKDCs in total DCs were analyzed by flow cytometry. The difference among each treated group was
analyzed by one-way ANOVA.
doi:10.1371/journal.pone.0038111.g005
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e38111Figure 6. RT induced the penetration of NKDCs in tumor tissue. Tumor samples from B cell deficient mice treated with either PBS, control
oligo, TLR9 agonist, RT (20 Gy) or RT+TLR9 agonist were stained with anti-CD11c and NK1.1 antibodies and the presence of NKDCs was visualized by
confocal microscope.
doi:10.1371/journal.pone.0038111.g006
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immune response, single fraction 20 Gy to the tumor might shape
the immune response toward a Th2-bias, which facilitates the
generation of tumor-reactive antibodies. Consistent with this
finding, a potent tumor-reactive antibody response was found in
mice receiving RT+TLR9 agonist treatment, while no detectable
tumor-reactive antibody titer was found in other cohorts.
However, the total serum IgG titer was not found significantly
different among various treatment cohorts. Thus single fraction
RT appears to generate a tumor-reactive humoral immune
response without influencing the total amount of antibody
generated. Furthermore, fluorescenct immunohistochemistry dem-
onstrated deposition of mouse IgG auto-antibodies in tumor tissue
in situ following RT.
Surprisingly, the tumoricidal effects of RT+TLR9 agonist
combination therapy were maintained in B cell-deficient mice,
suggesting that immune cells, other than B cells, contribute to the
control of tumor progression. Since TLR9 is also expressed on
NKDCs, we analyzed the phenotype of these cell subsets in mice
receiving combination therapy. TLR9 agonist significantly in-
Figure 7. RT+TLR9 agonist treatment prevents tumor metastasis and improves survival. The number of lung metastase in wild type
C57BL/6 mice treated with either PBS, control oligo, TLR9 agonist, RT (20 Gy) or RT+TLR9 agonist was counted and compared (A). The survival rate of
mice from each group after treatment was analyzed using Log-rank (Mantel-Cox) Test (B).
doi:10.1371/journal.pone.0038111.g007
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decreased the percentage of conventional DCs. Addition of RT
slightly downregulated the effect of TLR9 agonist while still
demonstrating a significant upregulation, compared to untreated
mice. Furthermore, TLR9 agonist activated NKDCs by upre-
gualting the expression of both CD80 and CD86, while RT
increased the tumor infiltration of NKDCs. Since NKDCs were
reported as a potent effect cell population that has direct cytotoxic
effect against tumor cells [16,35], these results indicate NKDCs
might contribute to the anti-tumor effects, induced by combined
TLR9 agonist and RT treatment. The mechanism of RT-induced
recruitment of lymphocytes and antibodies to tumor tissue is still
unclear. Previous studies showed that RT upregulated the
expression of VCAM-1 on the tumor vasculature [7] and induced
the release of chemokines, such as CXCL16 from tumor cells [8],
which may favor the trafficking of immune effector cells to the
tumor tissue.
The effect of RT dose and fractionation in immunomodulation
is unclear. Previous studies have shown that large single fraction of
RT (15–20 Gy) is effective in immunomodulation with CpG
oligonucleotode immunotherapy for murine fibrosarcoma [30].
Similarly, a single fraction of 15 Gy induced melanoma-specific T
cells and promoted intratumoral infiltration [9]. In contrast,
fractionated RT was found to be more effective than single
fraction RT in tumor control when combined with anti-CTLA4
antibody for a murine model of breast tumor [36]. However, the
last report used hypofractionated doses (6–8 Gy) during the
fractionated RT and thus it is possible that an ablative, large single
fraction (15–20 Gy) of RT or hypofractionated RT can induce
anti-tumoral immune response more effectively than conventional
fractionated RT (1.8–2 Gy single fraction). Possible explanation
might be that large fraction size induces translocation of cytosolic
calreticulin to the cell surface that promotes phagocytosis of
irradiated tumor cells by tumor infiltrating dendritic cells [37].
Therefore, ablative RT might induce an immunogenic tumor cell
death that can release tumor antigens, which are actively
phagocytosed by DCs and provide danger signals for DC
activation and induction of immune response [37]. It is possible
that primary tumor RT effectively generates a local tumor antigen
pool for APCs [38], such as, TLR9 agonist-activated pDCs, which
then uptake the tumor antigens and migrates to the lymph nodes
where it stimulates the Th2 cells to elicit a humoral immune
response. In addition, the danger signals induced by RT in dying
tumor cells and the modulation of intratumoral cytokine melieu
potentially plays a critical role in eliciting tumor-specific immune
response. Further studies are ongoing on how RT modifies the
tumor microenvironment to favor the induction of tumor specific
immune response.
In summary, the immunomodulatory effects of RT significantly
enhance the efficacy of immunotherapy with TLR9 agonists.
RT+TLR9 agonist therapy induced tumor-specific IgG auto-
antibodies, and stimulated proliferation and activation of TLR9-
expressing B cells, pDCs and NKDCs. The immunomodulatory
effects of the combination therapy improved local control of RT
and reduced systemic pulomonary metastases, thus providing
a strong rationale for combining RT with TLR9 agonist
immunotherapy for improved loco-regional and systemic tumor
therapy. Finally, we recently demonstrated that systemic admin-
istration of the synthetic TLR9 agonist protects against intestinal
injury and mucositis in radiation-induced gastrointestinal syn-
drome, without conferring any radioprotection to abdominal
tumors [39]. Thus, TLR9 agonist could improve the therapeutic
ratio of RT by providing radioprotection of normal moucosal
tissues, while increasing the tumoricidal effects of primary tumor
RT and induction of systemic anti-tumoral immunity for
eradication of systemic metastases.
Supporting Information
Figure S1 Detection of T cell response in mice treated
with TLR9 agonist and/or RT by ELISpot assay.
Splenocytes from control wildtype and B cell deficient mice or
mice treated with either TLR9 agonist, control oligo, RT or
combined RT and TLR9 agonist were cocultured with either
medium, PMA+Ionomycin or 3LL cells. The 3LL-specific IFN-c
releasing splenocytes were detected by ELISpot assay.
(TIF)
Table S1 Lymphocyte population in wildtype and B cell
deficient mice (n=5). Splenocytes from naı ¨ve wildtype and B
cell deficient mice were stained with fluorophore conjugated
antibodies against CD3, B220, NK1.1 and CD11c and were
analyzed by flow cytometry. Percentage of each lymphocyte subset
was calculated using Flowjo software.
(DOCX)
Table S2 Percentage of DC subsets in B cell deficient
mice treated with TLR agonist and/or RT. Splenocytes
from control B cell deficient mice or mice treated with either
TLR9 agonist, control oligo, RT or combined RT and TLR9
agonist were stained with fluorophore conjugated antibodies
against B220, NK1.1 and CD11c. Stained cells were analyzed
by flow cytometry and percentage of each DC subset was
calculated using Flowjo software.
(DOCX)
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